G&E Herbal Biotechnology Co., Ltd.

TPEX:4911 Stock Report

Market Cap: NT$3.3b

G&E Herbal Biotechnology Balance Sheet Health

Financial Health criteria checks 6/6

G&E Herbal Biotechnology has a total shareholder equity of NT$774.6M and total debt of NT$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are NT$874.9M and NT$100.2M respectively. G&E Herbal Biotechnology's EBIT is NT$93.4M making its interest coverage ratio -16.9. It has cash and short-term investments of NT$324.1M.

Key information

0%

Debt to equity ratio

NT$0

Debt

Interest coverage ratio-16.9x
CashNT$324.13m
EquityNT$774.65m
Total liabilitiesNT$100.22m
Total assetsNT$874.86m

Recent financial health updates

Recent updates

G&E Herbal Biotechnology (GTSM:4911) Is In A Strong Position To Grow Its Business

Apr 20
G&E Herbal Biotechnology (GTSM:4911) Is In A Strong Position To Grow Its Business

G&E Herbal Biotechnology (GTSM:4911) Is In A Strong Position To Grow Its Business

Jan 08
G&E Herbal Biotechnology (GTSM:4911) Is In A Strong Position To Grow Its Business

Financial Position Analysis

Short Term Liabilities: 4911's short term assets (NT$357.3M) exceed its short term liabilities (NT$98.9M).

Long Term Liabilities: 4911's short term assets (NT$357.3M) exceed its long term liabilities (NT$1.3M).


Debt to Equity History and Analysis

Debt Level: 4911 is debt free.

Reducing Debt: 4911 has not had any debt for past 5 years.

Debt Coverage: 4911 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 4911 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/09 08:41
End of Day Share Price 2025/01/09 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

G&E Herbal Biotechnology Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Regina LeeJih Sun Securities Investment Consulting Co., Ltd.
Evana ChenMasterlink Securities Corp.